Abstracts tagged "Nonsteroidal antiinflammatory drugs (NSAIDs) and osteoarthritis"

Abstract Number: 2350 • 2018 ACR/ARHP Annual Meeting
Examining Ethnic Differences in Osteoarthritis (OA) Patients’ Knowledge and Attitudes Regarding Prescription Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Hana Masood¹, Michael J. Hannon², C. Kent Kwoh¹, Jazmin Dagnino³ and Ernest Vina⁴, ¹Medicine, Division of Rheumatology, University of Arizona School of Medicine, University of Arizona Arthritis Center, Tucson, AZ, ²Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³University of Arizona Arthritis Center, Tucson, AZ, ⁴University of Arizona School of Medicine, University of Arizona Arthritis Center, Tucson, AZ
Background/Purpose: NSAIDs are commonly prescribed for the treatment of OA. While there are documented differences between Hispanics and non-Hispanic whites (NHWs) in their treatment preferences…
Abstract Number: 2232 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Glucosamine, Chondroitin Sulfate, Their Combination, Celecoxib,Non-Selective Non-Steroidal Anti-Inflammatory Drugs, and Placebo in Treating Knee Osteoarthritis
Vishvas Garg¹, Dennis Raisch², Ning Yan Gu³, Matthew E Borrego³ and Daniel O. Clegg⁴, ¹College of Pharmacy, University of New Mexico (at the time of research), Grayslake, IL, ²College of Pharmacy, University of New Mexico, Albuquerque, NM, ³University of New Mexico, Albuquerque, NM, ⁴Rheumatology, George Wahlen VA Medical Center/University of Utah, Salt Lake City, UT
Background/Purpose: Knee osteoarthritis (KOA) affects 13.8% of the US population aged ≥26, causing significant burden-of-illness. We compared the cost-effectiveness of conventional medicines such as non-steroidal…
Abstract Number: 1130 • 2012 ACR/ARHP Annual Meeting
The Effect of Age On the Number of Osteoarthritis Flares with Continuous Versus Intermittent Celecoxib Treatment
George H. Sands, Pritha Bhadra and Margaret Noyes Essex, Pfizer, Inc, New York, NY
Background/Purpose: Continuous nonsteroidal anti-inflammatory drug (NSAID) treatment is significantly more efficacious than intermittent dosing1during 22-weeks in preventing flares in patients with osteoarthritis (OA) of the…
Abstract Number: 261 • 2012 ACR/ARHP Annual Meeting
Effect of Advancing Age On the Gastrointestinal Safety of Celecoxib Versus Nonselective Nonsteroidal Anti-Inflammatory Drugs: A Post Hoc Analysis of GI-Reasons
Lee S. Simon¹, Byron Cryer², Gurkirpal Singh³, Chunming Li⁴ and Margaret Noyes Essex⁵, ¹SDG LLC Consulting, West Newton, MA, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer, Inc, New York, NY
Background/Purpose: Celecoxib use was associated with a lower risk of clinically relevant upper and lower GI events than nonselective (ns)NSAIDs in patients (≥ 55 years)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].